Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-01

Study Completion Date

2017-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study

NCT01935908

Subarachnoid Hemorrhage Seizures

WITHDRAWN PHASE4

Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

NCT00618436

Traumatic Brain Injury Subarachnoid Hemorrhage

COMPLETED PHASE4

Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage

NCT02631759

Acute intraCerebral Haemorrhage

COMPLETED PHASE3

Seizure Prophylaxis in Aneurysm Repair

NCT01801072

Intracranial Aneurysms Seizure

COMPLETED PHASE4

Prevention of Post-traumatic Seizures With Levetiracetam

NCT00566046

Epilepsy, Post-Traumatic

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subarachnoid Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Brief LEV

Administration of three days of levetiracetam twice daily after SAH

Group Type OTHER

Brief LEV

Intervention Type OTHER

Levetiracetam 1000mg BID x 3 days for prophylaxis

Extended LEV

Administration of levetiracetam twice daily after SAH

Group Type OTHER

Extended LEV

Intervention Type OTHER

Levetiracetam 1000mg BID for length of hospital stay for prophylaxis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brief LEV

Levetiracetam 1000mg BID x 3 days for prophylaxis

Intervention Type OTHER

Extended LEV

Levetiracetam 1000mg BID for length of hospital stay for prophylaxis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \>18 years of age
2. Diagnosis of spontaneous SAH

Exclusion Criteria

1. SAH secondary to trauma or arteriovenous malformation
2. Early death (defined as death within 3 days of presentation)
3. Known allergy to levetiracetam
4. Know seizure history on chronic AEDs
5. Pregnancy
6. Current incarceration

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No